LifeTech ScientificFRA:81X -0.71%96 ROA % is 3.59% as of Dec. 2025, which is 59% below its 10-year median of 8.77. GuruFocus rates FRA:81X with a GF Score™ of 96/100 and a GF Value™ of €0.21. The stock has 4 warning signs investors should review. Among 857 Medical Devices & Instruments companies, LifeTech Scientific ranks better than 61.61% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. LifeTech Scientific's annualizedNet Income for the quarter that ended in Dec. 2025 was €22.5 Mil.
LifeTech Scientific's average Total Assets over the quarter that ended in Dec. 2025 was €625.9 Mil. Therefore, LifeTech Scientific's annualized ROA % for the quarter that ended in Dec. 2025 was 3.59%.
The historical rank and industry rank for LifeTech Scientific's ROA % or its related term are showing as below:
FRA:81X'
s ROA % Range Over the Past 10 Years
Min: 2.94 Med: 8.77 Max: 13.3
Current: 2.94
During the past 13 years, LifeTech Scientific's highest ROA % was 13.30%. The lowest was 2.94%. And the median was 8.77%.
FRA:81X's ROA % is ranked better than 61.61% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.54
vs FRA:81X: 2.94
LifeTech Scientific (FRA:81X) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
LifeTech Scientific ROA % Related Terms
LifeTech Scientific ROA % Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LifeTech Scientific's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's ROA % distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
LifeTech Scientific (FRA:81X) has a ROA % of 3.59% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on LifeTech Scientific and its competitors. This is 59% below median its historical median of 8.77. Over the past decade, LifeTech Scientific's ROA % has ranged from 2.94 to 13.30. According to the industry distribution chart, LifeTech Scientific ranks #329 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 38.4%.
Is LifeTech Scientific's ROA % too high?
LifeTech Scientific's current ROA % of 3.59% is 59% below median its 10-year median of 8.77. Over the past 10 years, this metric has ranged from a low of 2.94 to a high of 13.30. The Medical Devices & Instruments industry median ROA % is 0.54. LifeTech Scientific's value of 3.59% is 564.8% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #329 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #329 out of 857 companies for ROA %. This puts LifeTech Scientific in the upper half of its industry. The industry median ROA % is 0.54. LifeTech Scientific's value of 3.59% is 564.8% above this benchmark. Historically, LifeTech Scientific's own ROA % has ranged from 2.94 to 13.30 over the past decade. While the company's 10-year median is 8.77 vs. the industry median of 0.54, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.54, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current ROA % of 3.59% is 564.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current ROA % is 3.59%, which is 59% below median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (FRA:81X) has a current ROA % of 3.59%. The stock's GF Value™ is €0.21, compared to a current price of €0.14 — trading 33.3% below its estimated fair value. The current ROA % is 3.59%, which is 59% below median its 10-year median of 8.77 and 564.8% above the Medical Devices & Instruments industry median of 0.54. LifeTech Scientific's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For LifeTech Scientific (FRA:81X), the current ROA % is 3.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (FRA:81X) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of €0.14 is trading 33.3% below its estimated GF Value™ of €0.21.
Key valuation signals for FRA:81X:
ROA %: 3.59% (59% below median its 10-year median of 8.77)
GF Value™: €0.21 vs. price of €0.14 (33.3% below fair value)
Industry Position: 564.8% above the Medical Devices & Instruments median (#329 of 857)
No single metric tells the full story. See the FRA:81X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
96GF Score
Get the complete analysis for FRA:81X
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:81X has been successfully added to your 
